So far, only one study has shown that in breast cancer, overexpression of Fra-2 is associated with a more aggressive tumour phenotype, suggesting that Fra-2 may be involved in breast cancer progression in vivo (Milde-Langosch et al. 2008). This evidence concerns the gene FOSL2 and breast cancer.